Diflazon (fluconazole) solution for infusions 2 mg/ml. 100 ml. №1 vial


Manufacturer: France



Treatment of such diseases in adults: cryptococcal meningitis; the coccidioidomycosis; invasive candidiasis; candidiasis of the mucous membranes, including oropharyngeal candidiasis and esophageal candidiasis, candiduria, chronic candidiasis of the skin and mucous membranes; chronic atrophic candidiasis (candidiasis caused by the use of dentures) when local dental hygiene products are ineffective; vaginal candidiasis, acute or recurrent when local therapy is not appropriate; Candida balanitis when local therapy is not appropriate; dermatomycosis, including foot mycosis, smooth skin mycosis, inguinal dermatomycosis, multi-colored lichen, and Candida skin infections when systemic therapy is inappropriate; dermatophytic onychomycosis, when the use of other drugs is inappropriate. Prevention of such diseases in adults: recurrence of cryptococcal meningitis in patients at high risk of developing it; relapse of oropharyngeal or esophageal candidiasis in patients with HIV at high risk of developing it; reducing the frequency of recurrent vaginal candidiasis (4 or more cases per year); prevention of Candida infections in patients with long-term neutropenia (for example, patients with malignant blood diseases who receive chemotherapy, or patients with hematopoietic stem cell transplantation).